We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: Abbott Labs discovers, develops, manufactures & sells a diversified line of health care products. Established Pharmaceuticals Division includes branded generics business in the emerging markets. Medical Devices unit includes the diabetes care, vision care & vascular businesses. Diagnostics unit manufactures and markets diagnostic systems and tests in four business lines core laboratory, molecular, point of care and rapid diagnostics. Nutrition unit includes a broad line of pediatric and adult nutritional products. Abbott acquired CFR Pharmaceuticals, Tendyne Holdings, Inc., St. Jude Medical and Alere Inc. On the other hand, Abbott sold its developed markets branded generics pharmaceuticals business to Mylan. Abbott retained the branded generics pharmaceuticals business in emerging markets. Abbott sold its animal health business to Zoetis Inc and divested its vision care business, Medical Optics, to Johnson & Johnson.
- Recent ABT Stock Price: $109.95
- Yearly Gain for ABT stock: -9.82%
- Market Cap for ABT stock: $193.54B
- P/E Ratio for ABT stock: 28.399
Will ABT's stock price go up? Is there an accurate ABT stock forecast available?
TipRanks.com reports that Abbott Labs currently has 11 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $123.82. The target pricing ranges from a high ABT forecast of $133.00 down to a low forecast of $107.00. Abbott Labs (ABT)’s last closing stock price was $109.95 which would put the average price target at 12.61% upside.
In addition, TradingView issued a Neutral rating for ABT stock over the next month, Barchart.com has a buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on ABT stock.
Other analysts covering ABT include:
- Jayson Bedford of Raymond James issued a Buy rating with the price target of $ 123 on 1 day ago
- Rick Wise of Stifel Nicolaus issued a Buy rating with the price target of $ 125 on 1 day ago
- Anthony Petrone of Mizuho Securities issued a Hold rating with the price target of $ 110 on 1 day ago
- Lee Hambright of Bernstein issued a Buy rating with the price target of $ 132 on 1 day ago
If you are wondering if ABT is a good stock to buy, here are 3rd party ratings for ABT stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Neutral
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: buy
- Zacks.com: Hold, Top 37% (93 out of 249)
What is the sentiment on the street regarding Abbott Labs? (Current ratings compiled by TipRanks.com)
- News Sentiment for ABT stock: Neutral
- Blogger Consensus for ABT stock: Bullish
- Media Buzz for ABT stock: Very High
- Insider Signal for ABT stock: n/a
- Investor Sentiment for ABT stock: Very Negative
- Hedge Fund signal for ABT stock: Negative
The stock market is extremely volatile, and you need to do your own research on ABT stock including scouring the social networks like ABT StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for ABT stock chart >>
Summary: Iovance Biotherapeutics is a clinical-stage pharmaceutical company primarily focused on the development and commercialization of novel T cell-based cancer immunotherapies. These immunotherapies use Generation 2 ('Gen 2') tumor infiltrating lymphocyte (TIL), which harnesses the power of a patient's own immune system to eradicate cancer cells.
- Recent IOVA Stock Price: $8.16
- Yearly Gain for IOVA stock: -44.40%
- Market Cap for IOVA stock: $1.22B
- P/E Ratio for IOVA stock: -3.102
Will IOVA's stock price go up? Is there an accurate IOVA stock forecast available?
TipRanks.com reports that Iovance Biotherapeutics currently has 10 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $22.78. The target pricing ranges from a high IOVA forecast of $38.00 down to a low forecast of $6.00. Iovance Biotherapeutics (IOVA)’s last closing stock price was $8.16 which would put the average price target at 179.17% upside.
In addition, TradingView issued a Buy rating for IOVA stock over the next month, Barchart.com has a Weak sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on IOVA stock.
Other analysts covering IOVA include:
- Colleen M. Kusy of Robert W. Baird issued a Buy rating with the price target of $ 25 on 3 days ago
- Geulah Livshits of Chardan Capital issued a Buy rating with the price target of $ 29 on 4 days ago
- Mara Goldstein of Mizuho Securities issued a Buy rating with the price target of $ 30 on 4 days ago
- Asthika Goonewardene of Truist Financial issued a Buy rating with the price target of $ 17 on 4 days ago
If you are wondering if IOVA is a good stock to buy, here are 3rd party ratings for IOVA stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 33% (83 out of 249)
What is the sentiment on the street regarding Iovance Biotherapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for IOVA stock: Very Bullish
- Blogger Consensus for IOVA stock: Bullish
- Media Buzz for IOVA stock: Very High
- Insider Signal for IOVA stock: Positive
- Investor Sentiment for IOVA stock: Neutral
- Hedge Fund signal for IOVA stock: Very Negative
The stock market is extremely volatile, and you need to do your own research on IOVA stock including scouring the social networks like IOVA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for IOVA stock chart >>
Summary: Rain Oncology Inc. is a late-stage precision oncology company developing therapies which target oncogenic drivers to genetically select patients. The company's lead product candidate includes milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex which reactivates p53. Rain Oncology Inc., formerly known as Rain Therapeutics Inc., is based in NEWARK, Calif.
- Recent RAIN Stock Price: $10.02
- Yearly Gain for RAIN stock: 26.90%
- Market Cap for RAIN stock: $334.19M
- P/E Ratio for RAIN stock: -3.733
Will RAIN's stock price go up? Is there an accurate RAIN stock forecast available?
TipRanks.com reports that Rain Therapeutics currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $18.14. The target pricing ranges from a high RAIN forecast of $29.00 down to a low forecast of $12.00. Rain Therapeutics (RAIN)’s last closing stock price was $10.02 which would put the average price target at 81.04% upside.
In addition, TradingView issued a Buy rating for RAIN stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on RAIN stock.
Other analysts covering RAIN include:
- Sam Slutsky of LifeSci Capital issued a Buy rating with the price target of $ 17 on 4 days ago
- Graig Suvannavejh of Mizuho Securities issued a Buy rating with the price target of $ 18 on 4 days ago
- Soumit Roy of JonesTrading issued a Buy rating with the price target of $ 20 on 4 days ago
- Joseph Catanzaro of Piper Sandler issued a Buy rating with the price target of $ 15 on 1 week ago
If you are wondering if RAIN is a good stock to buy, here are 3rd party ratings for RAIN stock:
- TipRanks.com: Strong Buy
- TradingView.com: Buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Buy, Top 33% (83 out of 249)
What is the sentiment on the street regarding Rain Therapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for RAIN stock: Very Bullish
- Blogger Consensus for RAIN stock: Bullish
- Media Buzz for RAIN stock: High
- Insider Signal for RAIN stock: Positive
- Investor Sentiment for RAIN stock: Very Positive
- Hedge Fund signal for RAIN stock: Neutral
The stock market is extremely volatile, and you need to do your own research on RAIN stock including scouring the social networks like RAIN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for RAIN stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
